Study finds doctors becoming even less accessible when it comes to meeting with drug reps
The number of physicians willing to meet with pharmaceutical representatives has fallen again this year, according to the latest AccessMonitor report, a study conducted by consulting firm ZS Associates (Evanston, IL) that examines how often physicians and other prescribers will meet with pharmaceutical sales reps.
More than 20 percent of the physicians deemed "rep-accessible" in a late 2009 AccessMonitor study have fallen to "rep-neutral" status, and 11 percent of those previously considered "rep-neutral" are now rated as "rep-inaccessible." Additionally, the study found that the physicians considered "rep-accessible" have become more discriminating in regards to who they will meet with, and the number of "rep-inaccessible" prescribers rose from 6 percent to 9 percent.
To deal with the rapidly falling number of physicians who will meet with their reps, the pharmaceutical industry is adapting its sales and marketing strategies.
"Sales management should accept that you can't reach these doctors simply by telling the reps to 'try harder,'" says Chris Wright, principal and leader of the pharmaceutical practice at ZS Associates. "Instead, managers must modify the call plan to connect best with each individual physician."
Many progressive pharmaceutical companies have responded to the increasing difficulty in gaining access to physicians by adopting a new sales strategy called "differential resourcing," which matches sales resources to local conditions and is more versatile than the traditional "one-size-fits-all" sales models previously used.
"While [differential resourcing] requires a rather complex change to existing sales models, companies who adopted this approach quickly reduced their sales force-related costs by as much as 20 percent," says Wright. "Collectively, these companies now save themselves more then $500 million a year... In our view, implementing this practice across the board can save sales forces in the U.S. another $2 billion annually—all while giving individual representatives much-needed flexibility."
The AccessMonitor study tracks sales rep-related interactions of more than 500,000 physicians, nurse practitioners and other pharmaceutical prescribers nationwide, and monitors the planned and completed sales calls of more than 41,000 pharmaceutical reps.
Trending Data & Response Plans in the Cleanroom Setting
April 30th 2025Being proactive with and responsive to your environmental monitoring (EM) data helps prevent problems with cleanroom contamination. Learn more about EM and cleanroom best practices and to see how ABM can implement industry-leading cleanroom solutions for your facility.
ABM’s Digital Solution for Good Manufacturing Practices
April 30th 2025Learn how our digital GMP solution ensures compliance with high regulatory standards, and offers faster, more accurate data access. By utilizing a mobile app for data collection and a management dashboard for task visibility and validation, it goes beyond traditional paper methods to meet growing industry needs.